Key points are not available for this paper at this time.
Nuclear protein in testis carcinoma is a rare and highly aggressive carcinoma associated with a 70% mortality rate 1 year from diagnosis and a median survival of only 6.5 months. No established treatment protocol exists, although some success has been achieved using a multimodal approach including early surgical resection and adjuvant chemotherapy and radiation. Prior studies have not demonstrated successful treatment in the absence of upfront surgical resection. We describe the first reported case of a patient with unresectable nuclear protein in testis carcinoma treated successfully with definitive chemotherapy using the Scandinavian Sarcoma Group IX Protocol and concurrent radiation therapy, but without surgical resection.
Building similarity graph...
Analyzing shared references across papers
Loading...
Rachel Leeman
Kerice Pinkney
Julie A. Bradley
Journal of Pediatric Hematology/Oncology
Brigham and Women's Hospital
Dana-Farber Cancer Institute
University of Florida
Building similarity graph...
Analyzing shared references across papers
Loading...
Leeman et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d97995a1d151c65f68447d — DOI: https://doi.org/10.1097/mph.0000000000001865
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: